Arrowhead Pharmaceuticals transitions to commercial-stage company and prepares for Floza-silan launch
ARWR Arrowhead Pharmaceuticals Inc
$47.77 +1.31%
View chart & analysis → - 1Arrowhead Pharmaceuticals recorded a net loss of $724.2 million and total revenue of $450.8 million in fiscal year 2026.
- 2As of September 30, new brand patient prescriptions for REDEMPLO increased by 63% compared to the end of the previous quarter.
- 3Arrowhead Pharmaceuticals is preparing for the U.S. launch of Floza-silan for the treatment of severe hypertriglyceridemia in the second quarter of 2027.
So what's the key point?
Prescriptions for Arrowhead Pharmaceuticals' medication increased by 63% compared to the previous quarter. The company is expanding its business while preparing to launch a new treatment in the United States.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.